[ad_1]
Thursday 17 December 2020
After vaccination to the hospital.
Person in Alaska Suffers Allergic Shock
In clinical study, the Biontech and Pfizer vaccine proved to be well tolerated, but with proper medical history, serious side effects can occur. In the US, a newly vaccinated person suffers from allergic shock, like two people in the UK.
One person was hospitalized in Alaska due to an allergic reaction after a corona vaccination. The person from the city of Juneau complained of shortness of breath and reddening of the skin 10 minutes after vaccination, which were noted during the recommended observation period immediately after injection. The person who works in the health care system was still in the hospital for observation Wednesday, and a spokesman for the DHSS health department in Alaska said his condition was stable.
In the US, corona vaccines started on Monday. Beforehand, about 40,000 people had participated in a series of tests with the preparation from Biontech and Pfizer, which only resulted in mild side effects. There have also been two cases of allergic reactions in Britain since vaccination began. There, authorities had warned people with a “significant” medical history not to get vaccinated. These are the so-called rare anaphylactic shocks as a reaction to drugs, foods or vaccines. Even people who have to carry an adrenaline pre-filled syringe, an autoinjector, like the two affected people in the UK, should not get vaccinated at the moment.
The US drug regulatory agency, FDA, issued an emergency approval for the Biontech and Pfizer vaccine last week. On Thursday, an independent vaccination committee is supposed to examine a request from the American pharmaceutical company Moderna for its corona vaccine and then give a recommendation to the FDA. This could mean that a second vaccine could be approved in the United States this week.
A Pfizer spokesperson said Wednesday: “In the pivotal Phase 3 clinical trial, this vaccine was generally well tolerated and the Independent Data Monitoring Committee reported no serious safety concerns. The trial has enrolled more than 44,000 participants up to the date, of which more than 42,000 have received a second vaccine. “
